Bio-Techne earns exceptional free cash flow at 274% of net income, holds a Piotroski financial health score of 8 out of 9, and maintains high gross margins — but the Protein Sciences segment represents 72% of revenue, top-line revenue has declined 2% year-over-year, and the stock is trading above its resistance take-profit target with negative asymmetry.
Thesis pillars
- Protein Sciences Segment Concentration↓Deteriorating
- Exceptional Cash Conversion Quality→Stable
- Revenue Decline With Strong Cash Flow→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Aug 24, 2026
Bio-Techne Corp (TECH) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $72.69, but acceptable to hold if already in. Reasons: Concentration risk — Product: Protein Sciences segment (72.0%); Analyst target reached - limited upside remaining.
Bio-Techne develops, manufactures and sells life science reagents, instruments and services for research, diagnostics and bioprocessing markets worldwide, through two segments: Protein Sciences (about 72% of fiscal 2026 net sales) and Diagnostics and Spatial Biology (about 28%).... Read more
Hold if already holding. Not a fresh buy at $72.69, but acceptable to hold if already in. Reasons: Concentration risk — Product: Protein Sciences segment (72.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.1/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Bio-Techne Corp
About Bio-Techne Corp
Merck KGaA, Darmstadt, Germany agreed on June 25, 2026 to acquire Bio-Techne for $73.00 per share in cash, with closing expected by late 2026 or early 2027. The Minneapolis life sciences tools company, founded in 1976, employed approximately 3,000 people at June 30, 2026, introduced over 1,900 new products in fiscal 2026, and held rights to approximately 487 granted patents. Protein Sciences generated about 72% of fiscal 2026 net sales and Diagnostics and Spatial Biology about 28%.
Protein Sciences combines a Reagent Solutions division, selling cytokines, growth factors, antibodies and small molecules under brands such as R&D Systems, Tocris and Novus Biologicals, with an Analytical Solutions division offering immunoassays and ProteinSimple instruments. It sells directly in North America, Europe and China, through a distribution agreement with Thermo Fisher Scientific, and through distributors in China, Japan and other regions, and no single end-user customer exceeded 10% of segment net sales. Diagnostics and Spatial Biology includes Advanced Cell Diagnostics RNAscope assays, the Lunaphore COMET spatial platform, Asuragen kits and the Bio-Techne Diagnostic division, whose calibrators and controls are mostly sold under OEM agreements with instrument makers and can produce uneven quarterly revenue because of bulk lot scheduling. Most products are made in-house in North America, the U.K., Canada, Switzerland and China. No single supplier is material, though some qualified components may come from one or a few sources. The company held a 19.9% stake in cell culture device maker Wilson Wolf and plans to acquire the rest by the end of calendar 2027.
Show full overview
Two factors may shape the outlook. The merger remains subject to regulatory approvals and shareholder approval, and the proxy statement was filed on August 20, 2026. Geographic exposure is the second: approximately 48% of fiscal 2026 sales revenue came from outside the U.S., and one strategy is to expand in China, India and developing countries, which could expose results to trade barriers, currency swings and geopolitical tension. U.S. drug-pricing and healthcare policy changes could also weigh on certain end markets the company serves.
See also: Healthcare · Biotechnology
From Bio-Techne Corp's most recent 10-K filing, extracted October 18, 2026.
Recent developments
updated 2026-10-29Recent Developments — Bio-Techne Corp
Latest news
- NEWS Dow drops over 1,100 points as sinking tech stocks combine with jumping oil prices to drag markets down - Fortune — Fortune negative
- NEWS Tech stock hits 52-week high at 72.17 USD By Investing.com - Investing.com UK — Investing.com UK positive
- NEWS Some tech shares are plunging - what does that mean for the AI revolution? - BBC — BBC negative
- NEWS Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock? - Yahoo Finance — Yahoo Finance neutral
- NEWS Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock? - finance.yahoo.com — finance.yahoo.com neutral
Generated 2026-10-29T11:08:52Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductProtein Sciences segment72%10-K Item 1: 'The Protein Sciences segment is the larger of our two segments, representing approximately 72% of our net sales in fiscal 2026.'
- MEDIUMGeographicsales outside the U.S.48%10-K Item 1A: 'approximately 48% of our sales revenue in fiscal 2026 coming from outside the U.S.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $72.69, but acceptable to hold if already in. Reasons: Concentration risk — Product: Protein Sciences segment (72.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Analyst target $61.34 reached (−15.6%), stop $72.45 (−0.3%), A.R:R -1.0:1. Score 5.1/10, moderate confidence.
Analyst target $61.34 reached (−15.6% from $72.69); no take-profit level is published. Analyst target $61.34 reached (−15.6%), stop $72.45 (−0.3%), A.R:R -1.0:1. Stop-loss: $72.45.
Concentration risk — Product: Protein Sciences segment (72.0%); Analyst target reached - limited upside remaining; Near 52-week high (0.1% away).
Bio-Techne Corp trades at a P/E of 62.7 (forward 31.4). TrendMatrix value score: 3.0/10. Verdict: Hold.
20 analysts cover TECH with a consensus score of 3.5/5. Average price target: $71.
What does Bio-Techne Corp do?Bio-Techne develops, manufactures and sells life science reagents, instruments and services for research, diagnostics...
Bio-Techne develops, manufactures and sells life science reagents, instruments and services for research, diagnostics and bioprocessing markets worldwide, through two segments: Protein Sciences (about 72% of fiscal 2026 net sales) and Diagnostics and Spatial Biology (about 28%). Customers include academic and pharmaceutical researchers, cell and gene therapy developers, and diagnostics OEMs. On June 25, 2026 it agreed to be acquired by Merck KGaA for $73.00 per share in cash.